pancreatic endocrine carcinoma
Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:1798
Name pancreatic endocrine carcinoma
Definition An islet cell tumor that has_material_basis_in epithelial cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer pancreatic cancer islet cell tumor pancreatic endocrine carcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF K601E Trametinib pancreatic endocrine carcinoma predicted - resistant detail...
BRAF K601E Dabrafenib + Trametinib pancreatic endocrine carcinoma predicted - resistant detail...
BRAF V600E Vemurafenib pancreatic endocrine carcinoma predicted - sensitive detail...
VHL inact mut Belzutifan pancreatic endocrine carcinoma sensitive detail...
BRAF V600E Cobimetinib + Vemurafenib pancreatic endocrine carcinoma predicted - sensitive detail...
BRAF V600E Dabrafenib + Trametinib pancreatic endocrine carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01466036 Phase II Cabozantinib Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Completed USA 0
NCT02077933 Phase I Alpelisib + Everolimus Alpelisib + Everolimus + Exemestane Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors Completed USA | NLD | ITA | HUN | GBR | FRA | ESP | DEU 1
NCT02101918 Phase II Aflibercept Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery Completed USA 0
NCT02108782 Phase II Dovitinib Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Withdrawn 0
NCT02230176 Phase II Sunitinib Lutetium Lu 177 dotatate Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II (OCCLURANDOM) Completed FRA 0
NCT02273752 Phase II Everolimus Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated USA 0
NCT02315625 Phase II Everolimus Sunitinib Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery Terminated USA 0
NCT02575300 Phase II Ibrutinib Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Completed USA 0
NCT02687958 Phase II Everolimus Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin Unknown status ITA 0
NCT02893930 Phase II Sapanisertib Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery Completed USA 0
NCT02936323 Phase Ib/II PEN-221 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Completed USA | GBR 0
NCT03043664 Phase Ib/II Lanreotide acetate + Pembrolizumab Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET) Completed USA 0
NCT03049189 Phase III 177Lu-edotreotide Everolimus Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE) Active, not recruiting USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | CZE | CHE | BEL | AUT | AUS 1
NCT03074513 Phase II Atezolizumab + Bevacizumab Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors Active, not recruiting USA 0
NCT03411915 Phase I XmAb18087 A Study of XmAb18087 in Subjects With NET and GIST Completed USA 0
NCT03475953 Phase Ib/II Avelumab + Regorafenib A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) Recruiting FRA 0
NCT03670030 Phase II Nab-rapamycin A Study to Test the Effectiveness of ABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System Terminated USA 0
NCT03870399 Phase II Tamoxifen Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression (HORMONET) Completed USA | BRA 0
NCT03879694 Phase I Octreotide + Sargramostim + SurVaxM Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors Completed USA 0
NCT03891784 Phase II Abemaciclib Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors Active, not recruiting USA 0
NCT03901378 Phase II Carboplatin + Etoposide + Pembrolizumab Pembrolizumab Cisplatin + Etoposide + Pembrolizumab Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma Withdrawn USA 0
NCT03972488 Phase III Octreotide acetate Lutetium Lu 177 dotatate + Octreotide acetate Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (NETTER-2) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN 1
NCT03980925 Phase II Carboplatin + Etoposide + Nivolumab Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. Completed ESP 0
NCT04427787 Phase II Cabozantinib + Lanreotide acetate A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET (LOLA) Unknown status ITA 0
NCT04525638 Phase II Lutetium Lu 177 dotatate + Nivolumab A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours Unknown status ESP 0
NCT04919226 Phase III Fluorouracil + Leucovorin + Oxaliplatin 177Lu-edotreotide Everolimus Capecitabine + Temozolomide Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (COMPOSE) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | AUS 2
NCT05053854 Phase I Lutetium Lu 177 dotatate + Talazoparib PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours (PARLuNET) Recruiting AUS 0
NCT05247905 Phase II Lutetium Lu 177 dotatate Capecitabine + Temozolomide Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting USA 0
NCT05249114 Phase I Cabozantinib + Lutetium Lu 177 dotatate Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors Active, not recruiting USA 0
NCT05262556 Phase I Ipilimumab + Nivolumab + Thymoquinone TQ (Thymoquione) Formula With Nivolumab and Ipilimumab in Gastroenteropancreatic Neuroendocrine Carcinomas Active, not recruiting USA 0
NCT05364944 Phase I Debio 4126 + Lanreotide acetate Debio 4126 + Octreotide acetate A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (OXTEND-01) Terminated POL | ITA | ISR | GBR | FRA | ESP | DNK | DEU 0
NCT05477576 Phase Ib/II Everolimus Lanreotide acetate RYZ101 Sunitinib Octreotide acetate Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (ACTION-1) Recruiting USA | NLD | FRA | ESP | CAN | BRA | BEL 1
NCT05554003 Phase II Temozolomide Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study (MeTe) Recruiting ITA 0
NCT05568017 Phase II Y-90-DOTATOC Neoadjuvant PRRT With Y-90-DOTATOC in pNET Terminated ITA 0
NCT05599984 Phase I ABBV-706 ABBV-706 + Budigalimab ABBV-706 + Cisplatin ABBV-706 + Carboplatin Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors Active, not recruiting USA | ITA | ISR | FRA | ESP | DEU | AUS 3
NCT05610826 Phase Ib/II Lutetium Lu 177 dotatate Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver Withdrawn USA 0
NCT05652686 Phase I PT217 A Study of PT217 in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) Recruiting USA 0
NCT05687123 Phase I Lutetium Lu 177 dotatate + Sunitinib Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors Recruiting USA | CAN 0
NCT05701241 FDA approved Lanreotide acetate Octreotide acetate Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients (SAUNA) Recruiting NLD | BEL 0
NCT05746208 Phase II Lenvatinib + Pembrolizumab Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors Recruiting USA 0
NCT05841563 Phase I PM54 Clinical Trial of PM54 in Advanced Solid Tumors Patients. Recruiting USA | ESP | BEL 0
NCT05987176 Phase II Lutetium Lu 177 dotatate Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases (NELMAS) Recruiting GBR 0
NCT05988918 Phase II CEP-11981 Multicenter Trial of ESK981 in Patients With Select Solid Tumors Recruiting USA 0
NCT05997056 Phase II Nab-rapamycin Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors Recruiting USA 0
NCT06016855 FDA approved Lutetium Lu 177 dotatate Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors Recruiting USA 0
NCT06202066 Phase II Montanide ISA 51 + Sargramostim + SurVaxM + Temozolomide Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas Not yet recruiting USA 0
NCT06395402 Phase II Lutetium Lu 177 dotatate 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry (LUMOD-ID) Recruiting USA 0
NCT06943755 Phase II XL092 Everolimus Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors (STELLAR-311) Recruiting USA 1
NCT07006727 Phase I 225Ac-ETN029 Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors Recruiting USA | CAN 1